Clinical Trials

Clinical and histological results evaluation of an innovative Erbium:YAG laser technology for facial rejuvenation

Cir. plást. iberolatinoam.-Vol. 44 - Nº 2Mario A. Trelles*, Justo M. Alcolea**, Vladimir Khomchenko***, Mariano VÉLEZ****, Pedro MARTÍNEZ-CARPIO*****

Introduction and Objective: In recent years there has been a growing interest in the use of partially ablative laser technology in facial rejuvenation. Among the lasers developed for this purpose, the Erbium: YAG laser coupled to a modulated space ablation system (RecoSMA ® , Linline, Minsk, Belarus) deserves attention because it changes the traditional thermal deposit of the laser due to a push mechanic phenomenon. Our aim was to determine the effectiveness and safety of a new method of facial rejuvenation using an Er:YAG laser together with a system of spatially modulated ablation.

Methods: Twenty six women, phototypes II to V, with signs of moderate to severe facial aging were studied in relation to their chronological age. All patients received 2 treatments 3 weeks apart. At each session the entire face was treated. Photographs and biopsies were taken before the 1st treatment and 3 and 6 months after the 2nd treatment. Clinical effectiveness, tolerance, adverse effects, complications, clinical and histological changes were evaluated.

Results: Fine lines, wrinkles, and overall characteristics of skin ageing improved significantly (p < 0.0001). The mean of improvement in fine lines and wrinkles in both groups (A+B) was by 66.4 ± 9.4 (r= 45-85). Several signs of facial ageing improved an average by 76.2% ± 6.2 (r = 60 - 85%) at 3 months, and by 59.4% ± 9.6 (r= 40 - 75%) at 6 months.The patients were shown the before and after photographs and 85% were satisfied or very satisfied. It was observed that the results obtained decrease slightly in the evaluation at 6 months (62% satisfied patients) making additional treatment sessions necessary.

Conclusions: Compared to other lasers used for facial rejuvenation, results of this study showed to have additional benefits and an excellent effectivenesssafety ratio. We must take into account the decrease of positive results at 6 months, so additional sessions are required although patients must be warned previously.

* Cirujano Plástico, Instituto Médico Vilafortuny, Cambrils, Tarragona, España. ** Licenciado en Medicina y Cirugía., Máster en Medicina Estética, Clínica Alcolea, Barcelona, España. *** Físico, Research Department, Linline, Minsk. Bielorrusia. **** Dermatólogo, Servicio de Dermatología Hospital del Mar, Barcelona, España ***** Especialista en Bioquímica Clínica y Patología Molecular, Unidad de Investigación Clínica IMC Investiláser, Sabadell, Barcelona, España.


BelarusMedica 2019
26th International Specialized Forum